Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Brachial Plexus nerveblok versus standardpleje til lukket reduktion af distal radiusfraktur hos voksne - BLOCK-forsøget. et nationalt multicenter randomiseret kontrolleret forsøg

16. september 2026 opdateret af: Nordsjaellands Hospital

The aim of the project is to evaluate the beneficial and harmful effects of an ultrasound-guided brachial plexus nerve block for patients with a distal radius (wrist) fracture in the need of realignment of fractured bone endings without cutting the skin (closed reduction), in comparison to a haematoma block, which is standard care in Denmark.

Every participant will receive one of the following types of anaesthesia for the realignment of the wrist fracture:

  1. A nerve block of the arm (plexus brachialis block)
  2. A haematoma block, which is the current standard anaesthesia in the emergency departments.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

1716

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Capital Region
      • Hillerød, Capital Region, Danmark, 3400
        • Copenhagen University Hospital - North Zealand Hillerød

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults (age ≥ 18 years) with a distal radius fracture in need of closed reduction

Exclusion Criteria:

  • Patients who would never qualify for surgery according to local guidelines
  • Lack of informed consent
  • No Danish Central Person Register (CPR) number
  • Allergies to the trial medication
  • Distal radius fracture initially deemed to require surgery regardless of the outcome of the closed reduction
  • Open fractures (fracture-related wound requiring sutures)
  • Other fractures on the same extremity ((NOT including distal ulna fracture(s))
  • Bilateral distal radius fractures both requiring closed reduction
  • Concomitant medical or surgical condition taking priority over the closed reduction of the distal radius fracture.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intervention group

Ultrasound-guided brachial plexus nerve block. A total of 30 ml of lidocaine (10 mg/ml) with adrenaline (5 ug/ml) will be administered in multiple injections.

The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block

Aktiv komparator: Control group

Haematoma block with local anaesthetics i.e. lidocaine with adrenaline

Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Kumulativ andel af patienter med distal radiusfrakturoperation
Tidsramme: 90 dage efter lukket reduktion
90 dage efter lukket reduktion

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite outcome of treatment related complications
Tidsramme: 90 days after closed reduction

loco-regional neurological complications from affected arm, local anaesthetic systemic toxicity, soft tissue injuries (including skin injuries) related to the closed reduction procedure, infection at the site of needle puncture, vessel puncture requiring subsequent treatment (including compression), pneumothorax, allergic reaction, new bone or joint injury (e.g. dislocation or fracture) after the closed reduction and/or pulmonary embolism

90 days after closed reduction
Patient Rated Wrist Evaluation (PRWE)
Tidsramme: 90 days after closed reduction

The PRWE is a patient-reported outcome and the PRWE-score is calculated from the Danish-validated translation of the PRWE questionnaire

90 days after closed reduction
Maximum pain score in the affected wrist during closed reduction(s)
Tidsramme: 0-12 hours after the closed reduction

The pain outcomes are patient-reported as a Numerical Rating Scale (NRS) score on a scale from 0=no pain to 10=worst pain imaginable. If the patient has the closed reduction performed more than one time, the patient will be asked to report the worst pain experienced during all the attempts of a closed reduction.

0-12 hours after the closed reduction
Proportion of patients with unacceptable radiographic fracture position immediately after closed reduction
Tidsramme: 0 -24 hours after closed reduction

The radiographic fracture position is evaluated according to the American Academy of Orthopaedic Surgerons (AAOS) guidelines. The fracture position is unacceptable if the fracture has a radial shortening > 3 mm, > 10 degrees dorsal tilt of the articular surface of radius from a perpendicular line on the longitudianal axis of radius or intra-articular displacement or step-off > 2 mm.

0 -24 hours after closed reduction

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Antal forsøg brugt til lukket reduktion
Tidsramme: Umiddelbart efter lukket reduktion
Umiddelbart efter lukket reduktion
Andel af individuelle komplikationer i det sammensatte sekundære resultat
Tidsramme: 90 dage efter lukket reduktion
90 dage efter lukket reduktion
Pain at rest in the affected wrist immediately, 90 days, and 12 months after closed reduction
Tidsramme: 0-12 hours, 90 days and 12 months after closed reduction

The pain outcomes are patient-reported as a Numerical Rating Scale (NRS) score on a scale from 0=no pain to 10=worst pain imaginable.

0-12 hours, 90 days and 12 months after closed reduction
Maximum pain in the affected wrist within the first 24 hours after closed reduction
Tidsramme: 24-36 hours after the closed reduction.

The pain outcomes are patient-reported as an NRS score on a scale from 0=no pain to 10=worst pain imaginable.

24-36 hours after the closed reduction.
Proportion of patients with complex regional pain syndrome (CRPS)
Tidsramme: 90 days and 12 months after closed reduction

CRPS is defined according to the Budapest Criteria

90 days and 12 months after closed reduction
Disabilities of the Arm, Shoulder, and Hand (DASH) score
Tidsramme: 90 days and 12 months after closed reduction

DASH-score is calculated from the Danish-validated translation of the DASH questionnaire

90 days and 12 months after closed reduction
Patient Rated Wrist Evaluation (PRWE)
Tidsramme: 12 months after closed reduction

PRWE-score is calculated from the Danish-validated translation of the PRWE questionnaire

12 months after closed reduction
Quality of life (EQ-5D-5L) score
Tidsramme: 90 days and 12 months after closed reduction

The Danish translation of the EQ-5D-5L questionnaire is used and the EQ-5D-5L-score is calculated based on the Danish EQ-5D-5L value set

90 days and 12 months after closed reduction
Difficulty of closed reduction of the fracture
Tidsramme: Immediately after closed reduction

The doctor reported ease on a numeric rating scale from 0-10; 0=very easy, 10=very difficult)

Immediately after closed reduction
Discomfort related to the anaesthetic procedure
Tidsramme: 0-12 hours after closed reduction

The discomfort is a patient-reported outcome on a numeric rating scale from 0-10; 0=no discomfort, 10=very uncomfortable

0-12 hours after closed reduction
Overall satisfaction with the treatment 0 to 24 hours after initiation of the anaesthesia
Tidsramme: 24 hours after closed reduction

The overall satisfaction is a patient-reported outcome on a numeric rating scale from 0-10; 0=very unsatisfied, 10=very satisfied. When evaluating the treatment, the patient is specifically asked to include all elements of the treatment including: the anaesthetic (procedure and following effects), the experience during the closed reduction and the pain and general sensation in the arm/wrist in the first 24 hours after the treatment commencement.

24 hours after closed reduction
Proportion of patients with unacceptable radiographic position at first follow-up in the orthopaedic out-patient clinic (typically 10-14 days post-reduction)
Tidsramme: 10-14 days after closed reduction

The radiographic fracture position is evaluated according to the American Academy of Orthopaedic Surgerons (AAOS) guidelines. The fracture position is unacceptable if the fracture has a radial shortening > 3 mm, > 10 degrees dorsal tilt of the articular surface of radius from a perpendicular line on the longitudianal axis of radius or intra-articular displacement or step-off > 2 mm.

10-14 days after closed reduction
Proportion of patients having one or more serious adverse events (SAEs), including events related to loss of hand function
Tidsramme: Within 90 days after closed reduction

A SAE is defined as an adverse event that leads to the following incidents:

  • Death
  • Life threatening injury or disease
  • Severe or permanent disability
  • Admission to the hospital or prolongation of hospitalisation

Surgical reduction of the distal radius fracture, including relevant admission to hospital, will not be catagorised as a SAE.

Within 90 days after closed reduction
Proportion of patients having one or more adverse events (AEs)
Tidsramme: Within 24 hours after closed reduction

An AE is defined as any harmful and unintended event, sign, or symptom, that appear during the trial period, regardless of whether this AE is considered related to the treatment or not.

Within 24 hours after closed reduction

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Cecilie D Harwood, MD, PhD-fellow, Copenhagen University Hospital - North Zealand
  • Ledende efterforsker: Anne-Sofie Jellestad, MD, PhD-fellow, Copenhagen University Hospital - North Zealand

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. december 2024

Primær færdiggørelse (Anslået)

24. november 2026

Studieafslutning (Anslået)

24. august 2027

Datoer for studieregistrering

Først indsendt

6. november 2024

Først indsendt, der opfyldte QC-kriterier

6. november 2024

Først opslået (Faktiske)

7. november 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner